- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05203224
Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)
May 22, 2022 updated by: University of Melbourne
Patients presenting to the emergency department with acute ischemic stroke, who are are eligible for standard intravenous thrombolytic therapy within 4.5 hours of stroke onset will be assessed for major vessel occlusion to determine their eligibility for the trial.
All participants will receive intravenous tenecteplase and endovascular thrombectomy as standard care.
The trial is a Bayesian Optimised Phase 2 dose-finding umbrella trial (single arm versus objective performance criterion of 20% substantial reperfusion prior to endovascular thrombectomy based on the EXTEND-IA TNK trials NCT02388061, NCT03340493).
The aim is to determine the optimal dose of intravenous dornase alfa (recombinant human DNase 1) with sufficient promise to take forward in a seamless phase 2b/3 design.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bruce CV Campbell, MBBS PhD
- Phone Number: 0393427000
- Email: bruce.campbell@mh.org.au
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4102
- Recruiting
- Princess Alexandra Hospital
-
Contact:
- Carol Bendall
- Phone Number: +61 7 3176 1499
- Email: carol.bendall@health.qld.gov.au
-
Principal Investigator:
- Michael Devlin, MBBS
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Not yet recruiting
- Royal Adelaide Hospital
-
Principal Investigator:
- Timothy Kleinig, MBBS PhD
-
-
Victoria
-
Melbourne, Victoria, Australia, 3050
- Recruiting
- Royal Melbourne Hospital
-
Principal Investigator:
- Bruce Campbell, MBBS PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients presenting with acute ischemic stroke eligible, using standard criteria, to receive IV thrombolytics within 4.5 hours of stroke onset
- Patient's age is ≥18 years
- Intention to perform endovascular thrombectomy Imaging inclusion criteria
- Arterial occlusion on CTA or MRA of the ICA, M1, M2 or basilar artery
Exclusion Criteria:
- Intracranial hemorrhage (ICH) identified by CT or MRI
- Rapidly improving symptoms at the discretion of the investigator
- Pre-stroke mRS score of ≥ 4 (indicating previous disability)
- Hypodensity in >1/3 MCA territory or equivalent proportion of basilar artery territory on non-contrast CT
- Contraindication to imaging with contrast agents
- Any terminal illness such that patient would not be expected to survive more than 1 year
- Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
- Pregnant or lactating women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravenous Dornase alfa (DNase)
Patients will receive a single intravenous dose of dornase alfa (at either 0.125mg/kg, 0.25mg/kg, or 0.5mg/kg in escalating tiers), administered as a bolus over ~30 seconds.
|
Intravenous Dornase alfa
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with substantial angiographic reperfusion or absence of retrievable intracranial thrombus at initial angiogram without symptomatic intracerebral hemorrhage
Time Frame: 24 hours post-treatment
|
composite outcome of reperfusion on initial angiogram (day 0 - expanded Treatment In Cerebral Infarction [eTICI] 2b-3 or no retrievable intracranial thrombus) and assessment of symptomatic intracerebral hemorrhage on brain imaging 24h post-treatment.
eTICI 2b-3 indicates reperfusion of >50% of the initially involved arterial territory.
|
24 hours post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
modified Rankin Scale (mRS) at 3 months
Time Frame: 3 months post stroke
|
ordinal analysis versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline National Institutes of Health Stroke Scale (NIHSS) score.
mRS is a functional outcome/disability score from 0 (no disability) to 6 (death).
NIHSS is a neurological impairment score from 0 (no deficit) to 42 (death)
|
3 months post stroke
|
modified Rankin Scale (mRS) 0-1 or no change from baseline at 3 months
Time Frame: 3 months post stroke
|
versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline NIHSS score
|
3 months post stroke
|
modified Rankin Scale (mRS) 0-2 or no change from baseline at 3 months
Time Frame: 3 months post stroke
|
versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline NIHSS score
|
3 months post stroke
|
Proportion of patients with 8 point reduction in NIHSS or reaching 0-1 at 3 days (early neurological improvement)
Time Frame: 3 days post stroke
|
versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline NIHSS score
|
3 days post stroke
|
Proportion of patients with near-complete reperfusion (eTICI 2c/3) at conclusion of the endovascular procedure
Time Frame: day 0 (end of endovascular thrombectomy)
|
versus EXTEND-IA TNK I & II historical control
|
day 0 (end of endovascular thrombectomy)
|
Symptomatic intracranial hemorrhage (SICH)
Time Frame: 36 hours post treatment
|
Symptomatic intracranial hemorrhage includes any sub-arachnoid bleeding associated with clinical symptoms and symptomatic intracerebral hemorrhage (SICH).
SICH is defined as "Intracerebral hemorrhage (parenchymal hematoma type 2 - PH2 within 36 hours of treatment) combined with neurological deterioration leading to an increase of ≥4 points on the NIHSS from baseline, or death"
|
36 hours post treatment
|
Death due to any cause
Time Frame: up to 3 months post stroke
|
versus EXTEND-IA TNK I & II historical control, adjusted for age and baseline NIHSS
|
up to 3 months post stroke
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bruce CV Campbell, MBBS PhD, University of Melbourne
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 18, 2022
Primary Completion (Anticipated)
September 30, 2025
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
January 10, 2022
First Submitted That Met QC Criteria
January 10, 2022
First Posted (Actual)
January 24, 2022
Study Record Updates
Last Update Posted (Actual)
May 24, 2022
Last Update Submitted That Met QC Criteria
May 22, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MBC2101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymized individual patient data will be uploaded to the Virtual Stroke Trials Archive (http://www.virtualtrialsarchives.org/vista/) 2 years after the publication of the primary manuscript.
Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA steering committee.
IPD Sharing Time Frame
2 years after the publication of the primary manuscript
IPD Sharing Access Criteria
Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA steering committee.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Dornase Alfa
-
University Hospital TuebingenJoachim Riethmueller, Dr. med.UnknownLong Term VentilationGermany
-
Nicole HamblettUniversity of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...Completed
-
JHL Biotech, Inc.CompletedHealthy SubjectsNetherlands
-
Boston Children's HospitalBrigham and Women's Hospital; South Shore HospitalRecruiting
-
Genentech, Inc.Terminated
-
University of Colorado, DenverGenentech, Inc.CompletedOtitis MediaUnited States
-
University of JenaCompletedCystic Fibrosis | RhinosinusitisGermany
-
Azienda Ospedaliera di PadovaHoffmann-La RocheUnknown
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
Genentech, Inc.TerminatedCystic FibrosisUnited States